Evidence map›Paper›PMID 42714800›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2026

Population Pharmacokinetic Analysis of Everolimus Based on Albumin-Bilirubin Scores in Kidney Transplant Recipients.

Toshinori Hirai, Takahiko Aoyama, Akiharu Okamoto, Chihiro Shiraishi, Yasuhiro Tsuji, Kouhei Nishikawa, Takahiro Inoue, Takuya Iwamoto

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Toshinori HiraiDepartment of Pharmacy, Institute of Science Tokyo Hospital, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. t.hirai@tmd.ac.jp.ORCID http://orcid.org/0000-0002-3898-2068
Takahiko AoyamaLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi, Chiba, 274-8555, Japan.
Akiharu OkamotoDepartment of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Chihiro ShiraishiDepartment of Pharmaceutics, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, Fukuoka, 814-0180, Japan.
Yasuhiro TsujiLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi, Chiba, 274-8555, Japan.
Kouhei NishikawaDepartment of Nephro-Urologic Surgery and Andrology, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Takahiro InoueDepartment of Nephro-Urologic Surgery and Andrology, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Takuya IwamotoDepartment of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Funding

Kaken Pharmaceutical JP23K14409
6 · The paper itself

Abstract

BACKGROUND AND

objectiveSeveral hepatic function scores, including the albumin-bilirubin (ALBI) score, have been proposed to guide everolimus dosage adjustments in kidney transplant recipients. However, whether these scoring systems can be used to individualize the everolimus dosing regimen remains unclear. Hence, in this study, we aimed to individualize the everolimus dosing schedule using population pharmacokinetic analysis.

methodsIn this retrospective study, we enrolled adult kidney transplant recipients who received oral everolimus at Mie University Hospital. The population pharmacokinetic model was a one-compartment model with first-order absorption. Covariates for apparent clearance were tested using stepwise forward and backward methods. Monte Carlo simulations were performed to predict the probability of the target everolimus trough concentration.

resultsThe dataset included 36 patients with 861 everolimus trough concentrations [(median (range)] of [4.2 (0.6-12.9) ng/mL] and a median follow-up of 707 (7-2177) days. The median ALBI score was - 2.85 (- 3.19 to - 2.31), the median apparent clearance of everolimus was 7.96 L/h, and a significant decrease was observed at higher ALBI scores. Based on Monte Carlo simulation, patients with an ALBI score of - 2.60 required an everolimus dose of 0.5 mg and 0.75 mg twice daily to achieve the therapeutic range (3.0-8.0 ng/mL), whereas those with an ALBI score of - 1.39 required 0.5 mg twice daily.

conclusionsThe population pharmacokinetic model provided a dosing regimen for everolimus based on the ALBI score.

Identifiers

PMID42714800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.